ACSL1 as a main catalyst of CoA conjugation of propionic acid-class NSAIDs in liver

January 22, 2021

Kanazawa, Japan - Liver injury is a rare side effect of nonsteroidal anti-inflammatory drugs (NSAIDs), which are frequently used for daily pain control. This toxicity has been regarded as a "black box" and is mainly managed by an empirical approach, but there is not a clear understanding of the mechanism. Now, researchers from Japan have found that a bit of attention to the types and frequencies of NSAIDs could help people avoid liver injury.

In a study published recently in Biochemical Pharmacology, researchers from Kanazawa University have revealed that specific NSAIDs, including ibuprofen, are metabolized by one of the acyl-CoA synthetases, ACSL1, in a manner that can have toxic effects.

NSAIDs containing a specific chemical group, carboxylic acid, can form "conjugates" with coenzyme A (CoA) or glucuronic acid. Although these conjugates are suspected to cause toxicities, such as liver injury and anaphylaxis, the processes involved in CoA conjugation have been poorly understood, and researchers at Kanazawa University have aimed to address this.

"NSAID toxicities including liver injury and anaphylaxis had been considered to be caused by conjugates with glucuronic acid, another types of metabolite," says senior author of the study, Miki Nakajima. "Because a recent study demonstrated a robust interaction between ibuprofen and CoA, we wanted to investigate how a range of NSAIDs conjugated with CoA in the presence of liver enzymes."

To do this, the researchers performed enzymatic reactions involving human liver extracts, CoA, and representative medications from each of 10 classes of NSAIDs. They used a mass spectrometry method to identify interactions between the NSAIDs and CoA.

"The difference among NSAIDs was striking," explains Tatsuki Fukami, corresponding author. "We found that propionic acid-class NSAIDs, such as ibuprofen, had robust binding interactions with CoA, whereas other NSAIDs, such as salicylic acid, did not. This selectivity was likely determined by ACSL1."

In addition, CoA conjugates of propionic acid-class NSAIDs could strongly bind with liver proteins, while glucuronic acid conjugates of those same NSAIDs formed weaker bonds with liver proteins.

"Our findings suggest that the high covalent binding of CoA-conjugate of propionic acid-class NSAIDs to hepatocellular proteins leads to liver injury. Because there is a large interindividual variation in the hepatic expression of ACSL1 catalyzing CoA conjugation with propionic acid-class NSAIDs, this variation may account for the susceptibility to their toxicities," says Fukami.

Because pain control is an important medical problem for many people worldwide, this new information could help pharmaceutical companies to generate pain control options with fewer risks of severe side effects.
-end-


Kanazawa University

Related Liver Injury Articles from Brightsurf:

Eating less suppresses liver cancer due to fatty liver
Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan.

Study shows proof of concept of BioIVT HEPATOPAC cultures with targeted assay to evaluate bioactivation potential and drug-induced liver injury (DILI) risk
New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment.

Gene test can predict risk of medications causing liver injury
A team of scientists from Cincinnati Children's, Japan and Europe report in a study published Sept.

UTHealth's Cynthia Ju awarded NIH grants for liver injury research
Tiny solutions are being sought for big liver problems by a scientist at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).

Longevity protein SIRT6 also protects against fatty liver and fatty liver disease
SIRT6 regulates fat metabolism by activating another protein called peroxisome proliferator-activated receptor alpha (PPAR-alpha).

Lactobacillus balances gut microbiome and improves chronic-alcohol-induced liver injury
Researchers demonstrated that Lactobacillus rhamnosus can dose-dependently reestablish a balanced intestinal microbiome and counter the liver-damaging effects of alcohol consumption in mice to reverse the results of chronic alcohol-induced liver injury.

Immune cell identity crisis: What makes a liver macrophage a liver macrophage?
UC San Diego researchers investigated how a type of immune cell called a macrophage becomes specialized to the liver.

Liver transplants could be redundant with discovery of new liver cell
Researchers at King's College London have used single cell RNA sequencing to identify a type of cell that may be able to regenerate liver tissue, treating liver failure without the need for transplants.

New insights on liver injury in men taking body building supplements
In a study reported in Alimentary Pharmacology & Therapeutics, 44 men with liver injury, attributed to over-the-counter bodybuilding supplements, experienced a uniform and distinctive pattern of signs and symptoms that were often prolonged, difficult to treat, and accompanied by disability and weight loss.

Blocking platelets: A possible option to prevent fatty liver disease and liver cancer
Blood platelets which interact with liver cells and immune cells play a major role in the development of fatty liver disease, non-alcoholic fatty liver inflammation and liver cancer, scientists from the German Cancer Research Center (DKFZ) in Heidelberg and from Zurich University and University Hospital have now shown in a publication.

Read More: Liver Injury News and Liver Injury Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.